SCHEMBL5125697

SCHEMBL5125697

N[C@H](CCNCc1ccccc1)Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.56
HTR2B P41595 3/20 0.56
HTR2C P28335 2/20 0.56
CYP3A4 P08684 3/20 0.50
SIGMAR1 Q99720 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2D6 P10635 2/20 0.50
TP53 P04637 1/20 0.50
TSHR P16473 1/20 0.50
CYP2C19 P33261 1/20 0.50
ADRA2C P18825 2/20 0.47
SLC6A4 P31645 2/20 0.47
ADRA1A P35348 2/20 0.47
DRD3 P35462 2/20 0.47
MAPT P10636 2/20 0.47
LMNA P02545 1/20 0.47
OPRK1 P41145 1/20 0.47
SCN8A Q9UQD0 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5117524 0.96 HTR2A (0.55) HTR2AHTR2BHTR2CCYP3A4SIGMAR1
SCHEMBL4245195 0.79 DPP7 (0.55) HTR2AHTR2BHTR2CMAPTSCN8A
SCHEMBL5125694 0.79 HTR2A (0.54) HTR2AHTR2BHTR2CCYP3A4SIGMAR1
SCHEMBL20432313 0.79 HTR2A (0.60) HTR2AHTR2BHTR2CCYP3A4SIGMAR1
Hydrochloric Acid SCHEMBL11847984 0.79 MEN1 (0.62) HTR2AHTR2BHTR2CCYP3A4SIGMAR1
SCHEMBL13965832 0.77 HTR2A (0.58) HTR2AHTR2BHTR2CCYP3A4SIGMAR1
SCHEMBL13358929 0.77 SCN8A (0.46) HTR2AHTR2BHTR2CCYP3A4SIGMAR1
SCHEMBL22579188 0.77 KDM4E (0.63) HTR2AHTR2BHTR2CCYP3A4SIGMAR1
SCHEMBL30762155 0.76 HTR2A (0.70) HTR2AHTR2BHTR2CCYP3A4SIGMAR1
SCHEMBL8276492 0.75 BACE1 (0.62) HTR2AHTR2BHTR2CBCHEBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 US disclosed
US-7294642-B2 1,3-Diamino-2-hydroxypropane pro-drug derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 HTR2A 637/4885HTR2B 463/4885HTR2C 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.